Carboxylesterase 1 is the enzyme involved in methylphenidate (MPH) metabolism. The aim of this study was to evaluate the association between a À75 T4G polymorphism and appetite reduction in children with attention-deficit/hyperactivity disorder (ADHD). A sample of 213 children with ADHD was investigated. The primary outcome was appetite reduction measured by the Barkley Stimulant Side Effect Rating Scale applied at baseline, at 1 and 3 months of treatment. MPH doses were augmented until no further clinical improvement or significant adverse events occurred. The G allele presented a trend for association with appetite reduction scores (P ¼ 0.05). A significant interaction between the G allele and treatment over time for appetite reduction scores was also observed (P ¼ 0.03). The G allele carriers presented a higher risk for appetite reduction worsening when compared with T allele homozygotes (odds ratio ¼ 3.47, P ¼ 0.01). The present results suggest an influence of carboxylesterase 1 À75 T4G polymorphism on the worsening of appetite reduction with MPH treatment in youths with ADHD.
INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common child and adolescent psychiatric disorders, affecting around 5% of children worldwide. 1 Stimulants like methylphenidate (MPH) and amphetamine are widely recognized as the first-line treatment for ADHD, and they have been prescribed for more than 60 years. 2 The use of MPH in children and adolescents with ADHD is associated to rates of effectiveness around 70% and the medication is generally well tolerated. 3 One of the most recognized brain effect of MPH and its potential mechanism of action for improvement of ADHD symptoms is dopamine transporter blockade, although MPH blocks efficiently norepinephrine transporter as well. 4, 5 Most of the studies investigating MPH pharmacogenetics in ADHD focused on genetic variants of drug targets, such as transporters and receptors, and have emphasized on symptom reductions. 6, 7 Few studies addressed tolerability during MPH treatment. 8, 9 These investigations suggest that the prediction of adverse-event risk and medication tolerability would be a more clinically useful application, because adverse events are major impediments to long-term treatment adherence. 8, 9 Surprisingly, little attention has been paid to the genetic variability of drug metabolism in the area of ADHD pharmacogenomics.
MPH has two chiral centers and there are four isomers, a d,l-erythro-methylphenidate pair and a d,l-threo-methylphenidate pair. Only the racemic mixture of the threo pair of enantiomers (d,lthreo-methylphenidate) is used therapeutically, because it has less adverse effects than the erythro pair. 10 The carboxylesterase 1 (CES1) gene encodes the main enzyme involved in MPH metabolism. In oral administration studies, the racemic d,l-methylphenidate undergoes stereoselective clearance to ritalinic acid before entering the systemic circulation. Then, plasma concentrations of d-methylphenidate are higher than those of l-methylphenidate, as the later is eliminated faster than d-methylphenidate. Zhu et al. 11 identified two CES1 variants with reduced enzyme activity in a compound heterozygote subject participating in an MPH pharmacokinetics study. The 428G-A transition in exon 4 of the CES1 gene results in glycineto-glutamate substitution (Gly143Glu), whereas a 1-bp deletion (780delT) in exon 6 produces a frameshift and premature truncation of the protein (Asp260fs). These variants led to elevated MPH blood concentrations and were associated with distinct patterns of hemodynamic response. Nemoda et al., 12 on the basis of five heterozygous patients, reported an association between CES1 Gly143Glu polymorphism and MPH dose. These authors suggested that carriers of the Glu allele required lower MPH doses. As these variants have low allele frequencies (o5%) in all ethnic groups so far investigated, 11 their usefulness for pharmacogenetics studies is small. Recently, Yamada et al. 13 resequenced the CES1 gene bidirectionally in 170 subjects, detecting genetic variants that were evaluated in relation to their potential usefulness in pharmacogenomic studies. Among the polymorphisms described, one, À75 T4G (rs3815583), located in the 5 0 -untranslated region presented a trend for association with hepatotoxicity determined by isoniazid use.
Adverse events associated to MPH are not severe, but may have an impact in the short-and long-term domains of functioning.
The most commonly reported MPH adverse event is appetite reduction with weight loss. 15--17 Independently of its duration, appetite reduction is one of the most frequent reasons for dose reduction or discontinuation of stimulant therapy. It is important to note that around 12% of subjects stop medication because of appetite reduction. 18--20 Therefore, the aim of the present study was to evaluate the association between this CES1 newly described polymorphism (À75 T4G) and appetite reduction in children and adolescents with ADHD.
SUBJECTS AND METHODS Subjects
The sample for this investigation included children and adolescents who were consecutively evaluated for 2 years in the ADHD Outpatient Clinic at the Hospital de Clinicas de Porto Alegre. Inclusion criteria for this investigation were as follows: ADHD diagnosis according to DSM-IV criteria, age between 4 and 17 years and drug-naive for MPH. The diagnoses of ADHD and comorbidities were achieved through a three-step process: application of semistructured interviews (Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version), diagnostic discussion in a clinical committee, and clinical evaluation with the child and his/her parents. Experienced child psychiatrists confirmed all generated diagnoses. 21, 22 During the study, 213 children fulfilled inclusion criteria to participate. The Ethical Committee of Hospital de Clínicas de Porto Alegre approved the study protocol. Parents provided written informed consent and probands provided verbal assent to participate.
Diagnostic procedures and clinical assessments
The primary outcome variable was appetite suppression measured through the parent-rated Barkley Stimulant Side Effect Rating Scale (BSSERS). 23 This scale is composed of 17 side effects commonly associated with MPH treatment. It is the most used rating scale for adverse events in psychopharmacological trials with MPH in ADHD. 22, 24 In this study, to avoid multiple testing, only the appetite reduction score was analyzed. This choice was based on the clinical relevance of this side effect for adherence to treatment. Appetite reductions were ranked on a 9-point scale from absence of this adverse event (score ¼ 0) to the most severe appetite suppression (score ¼ 9). The scale was applied by child psychiatrists blinded to genotype at baseline, and at 1 and 3 months of treatment. Patients were treated according to the program's protocol.
Dosages of short-acting MPH were augmented until no further clinical improvement was detected or until there were significant adverse events. 25 Clinical assessments were performed by child psychiatrists at baseline before medication, and after 1 and 3 months of MPH treatment. At baseline, psychiatrists prescribed MPH doses of 0.3 mg kg À1 per day. After 1 month, subjects received doses between 0.5--0.7 mg kg À1 per day, and at 3 months, they received doses of 1.0 mg kg À1 per day according to clinical improvement and adverse effects occurrence. If adverse effects emerged during tritation, doses were reduced to previously tolerated levels. MPH was administered preferentially twice daily (at 0800 and 1200 h), but an extra dose between 1700 and 1800 h was allowed for children needing continuous coverage during evenings. Psychiatrists were blinded to genotypes of patients.
Genotyping
DNA was extracted from whole-blood lymphocytes following the method described by Lahiri and Nurnberger. 26 The rs3815583 (À75 T4G) polymorphism was genotyped using a Taqman SNP genotyping assay (Applied Biosystems, Foster City, CA, USA), according to the manufacturer-recommended protocol for the TaqMan allelic discrimination system (7500 Real Time PCR System, Applied Biosystems).
Statistical analyses
The w 2 -test or Fisher's exact test was used for categorical variables; for continuous variables with and without normal distribution, Student's t-test and Wilcoxon--Mann--Whitney U-tests were used, respectively. Potential confounders evaluated were IQ, ADHD subtype, comorbid conditions (mood, anxiety and disruptive behavior disorder), age, sex, MPH dose, concomitant prescription of another medication, BSSERS baseline scores, and appetite reduction baseline scores. Potential confounders to be entered in models were defined on the basis of conceptual analyses of the literature and by means of a statistical definition (association with the study factor and with the outcome at Pp0.10). SPSS version 18.0 was used for these analyses (SPSS, Chicago, IL, USA).
Analyses of the effect of different genotypes on the efficacy of the treatment were performed using a mixed-effects model, which produces a flexible framework for the analysis of repeated measures while accounting for missing data (e.g., loss to follow-up). 8,9,27--30 The best covariance structure fitting the data was selected based on the one with the lowest Akaike information criterion value among those in which convergence has been achieved. Independent factors included in the model were treatment over time and group assignment (defined as the presence of the G allele). The appetite reduction baseline scores and the mean daily doses of MPH prescribed at baseline and at the 1-month assessment were included in the model as a covariate for conceptual reasons. All possible interactions were tested, but non-significant interactions were dropped in the final model using a backward elimination procedure. These analyses were performed with SAS 9.2 version using the Proc MIXED routine (SAS Institute, Cary, NC, USA). To evaluate effect size, the Cohen's f 2 that measures the ratio of variance explained to unexplained variance for the main and interactive effects 9,31 was estimated. A significance level of 5% was set for all analyses (except for potential confounders, as indicated previously). Tests were two-tailed.
RESULTS
From the 213 subjects investigated, 8 were excluded from the study, because their appetite reduction baseline scores were equal to 9 on the BSSERS; therefore, there was no room for further worsening. The estimated allele frequencies for the included subjects were 0.80 for the T allele and 0.20 for the G allele. The genotype frequencies were 0.63 for T/T homozygous individuals, 0.35 for G/T heterozygous individuals and 0.02 for G/G homozygous individuals. The genotype distribution did not deviate significantly from the Hardy--Weinberg equilibrium. Allele frequencies were similar to those described at the NCBI database for the same ethnic group. (http://www.ncbi.nlm.nih.gov). Owing to the low frequency of G/G homozygous individuals, they were grouped with G/T heterozygotes. Therefore, carriers of the G allele were compared with those without this allele (subjects homozygous for the T allele) to explore the effect of the presence of the G allele on outcomes.
Demographic and clinical characteristics of the patients according to the presence of the G allele are shown in Table 1 . Although borderline significant differences between the two genotype groups were observed for gender and ethnicity, these characteristics were not associated with the outcome (P40.10); therefore, these features were not considered as potential confounders. Although ethnicity was not a confounder, a secondary analysis was performed only with children of European descent with similar results (data not shown but available upon request). Figure 1 shows the trajectory of appetite reduction scores during MPH treatment based on findings from the mixed-effects model, including treatment over time and the presence of G allele as main effects, appetite reduction baseline scores and the mean daily MPH dose as covariates (conceptual confounders), and significant interactions between these factors during the 3 months of treatment (n ¼ 205). The full model for this analysis is provided in Supplementary Table S1 . An independent effect of treatment over time (F(2,270) ¼ 82.07, Po0.001) and of the appetite reduction baseline scores (F(1,189) ¼ 83.29, Po0.001) were found. The interaction between these two factors was statistically significant (F(2,267) ¼ 40.06, Po0.001). There is no significant effect of the daily mean MPH dose (F(1,181) ¼ 3.13, P ¼ 0.08) on the scores of appetite reduction. Moreover, a trend for the effect of the presence of G allele (F(1,197) ¼ 4.04, P ¼ 0.05, f 2 ¼ 0.02) and a significant interaction effect between the G allele and treatment over time (F(2,265) ¼ 3.71, P ¼ 0.03, f 2 ¼ 0.02) were also observed. Also, there was a trend for interaction between G allele and appetite reduction baseline scores (F(1,172) ¼ 4.05, P ¼ 0.05, f 2 ¼ 0.01). No third-order interactions were significant. The covariance structure with the lowest Akaike information criterion value was the Toeplitz one. The effect sizes of the investigated polymorphism and its interactions represent small clinical effects considering Cohen's suggestion that an effect size of less than 0.02 indicates a small effect. 31 As clinicians frequently assume that appetite reduction diminishes with time of treatment and our general findings suggest a major effect during the first month, post-hoc analyses dividing time in two periods (baseline to 1 month, and 1 month to 3 months) were performed. The findings for the first period were significant: The G allele was significantly associated with appetite reduction scores during treatment (F(1,201) ¼ 6.36, P ¼ 0.01). A significant interaction between the G allele and treatment over time for appetite reduction scores (F(1,202) ¼ 6.31, P ¼ 0.01) and an independent effect of treatment over time (F(1,202) ¼ 150,31, Po0.001) were also observed. Findings for the second period were not significant (data available upon request).
To closer assess the clinical relevance of the association observed, 118 subjects that started MPH treatment with an appetite reduction score equal to zero (no appetite suppression problem in the baseline) were selected for further analyses. For these analyses, scores above 6 were considered to be severe. Table 2 and Figure 2 shows that 34.1% of G carriers with zero score at baseline raised to the highest scores of appetite reduction Appetite reduction scores between 6--9.
CES1 polymorphism and MPH adverse reactions EM Bruxel et al (6--9) after 3 months of treatment, whereas only 13% of T homozygotes presented scores at this range after this time. The G allele carriers presented a 3.5 times higher risk to have highest appetite reduction scores when compared with T allele homozygotes (odds ratio ¼ 3.47, 95% confidence interval ¼ 1.38--8.77, P ¼ 0.01).
DISCUSSION
The present results suggest that worsening of appetite reduction due to MPH treatment in children and adolescents is associated with a À75 T4G single-nucleotide polymorphism at the CES1 gene. We are unaware of any previous studies investigating the role of this polymorphism in response to MPH treatment, even more assessing specifically adverse events. Genetic variants in CES1 gene may contribute to adverse drug reactions and increased sensitivity or resistance to drug treatment. Rare nonsynonymous variants in CES1 encode enzymes with impaired activities that dramatically alter the pharmacokinetics and drug response. The exact impact of À75 T4G polymorphism on the CES1 enzyme functionality is yet unknown, but, as it is located at the 5 0 -untranslated region, it could have an effect on gene regulation. It is possible that the G allele has reduced enzyme activity, and carriers of this allele might have higher plasma drug levels; therefore, patients with this genotype could be more prone to develop adverse reactions like appetite reduction. However, the small effect size of CES1 single-nucleotide polymorphism suggests that adverse effects as response to MPH might be influenced by several different polymorphisms. 7, 32 Thus, functional studies will be needed to investigate whether this single-nucleotide polymorphism affect the CES1 activity. The fact that MPH doses showed a trend for association in this protocol did not discard this possibility, as clinicians have incremented doses in each follow-up visit according to response and adverse events, with initial and follow-up doses that, although not fixed, were supposed to be targeted, respectively, around 0.3 and 0.7 mg kg À1 per day. So, the study design is not adequate to investigate the association between genotype and MPH dose. Most studies that used a fixed-dose range found that adverse effects are dose-dependent. 19,33--35 Appetite reduction due to MPH treatment has been reported by several studies. In 2004, a study demonstrated that MPH reduced energy intake by 23% at moderate doses (0.5 mg kg
À1
) versus placebo in obese men. 36 An open study demonstrated that atomoxetine, a nonstimulant drug also prescribed for ADHD treatment, prescribed conjointly with osmotic-release MPH was associated with significantly greater rates of mild-to-moderate loss of appetite compared with atomoxetine alone. 37 Several other studies confirmed that appetite reduction was not only significantly more prevalent with MPH than with placebo, but also one of the most prevalent and impairing short-term adverse event. 33, 35, 38, 39 Four different investigations assessed MPH pharmacogenetic effects on appetite reduction. A case--control study reported an association of the DAT1 9-repeat allele with appetite reduction in response to stimulant administration. This study was the first to examine the suppression of appetite ratings of MPH in relation to DAT1 genotype variation. 40 Leddy et al. 41 also demonstrated an effect MPH dose response on eating with DAT1 in ADHD youths. McGough et al. 9 described decreased vegetative symptoms, which included appetite reduction, in individuals homozygous for the long allele at the 5HTTLPR serotonin transporter gene. Nevertheless, no association between appetite reduction, and dopaminergic and serotonergic genes was found after the first month of treatment in part of the sample investigated herein. 21 The observational-naturalistic design of our study, moderate sample size and the absence of MPH plasma level information in our patients are limitations of the present study. We did not have a placebo arm in this trial, so we had no internal control to correct for any effect of time (e.g., regression to the mean) or expectancy bias. The worsening in appetite reduction scores in our sample was comparable to that previously reported in placebo-controlled trials. 38, 39 Although a placebo response was likely present in our study and decreased the power by reducing the measurement precision of drug action on appetite, it is unlikely that a placebo response was systematically related to the polymorphism assessed. In addition, we minimized the chance that the higher appetite reduction scores with MPH treatment detected in carriers of the G allele might be attributed to other events, because we performed an extensive assessment of potential confounders between groups with and without the G allele, a strategy not usually performed in previous pharmacogenomic investigations of ADHD, and we excluded those youths with the highest scores at baseline. Second, MPH was administered with no control of adherence by investigators. We cannot rule out that lack of adherence occurred to some extent in the remaining sample. Nevertheless, there was an important overall increase in appetite suppression according to the parents during follow-up. As usual, the challenge faced by research into the genetic basis of psychopharmacological drug responses is to identify genes of relative small effect against a background of substantial genetic and environmental variation. Additionally, selection bias and factors, such as socioeconomic status or health care, may differ between individuals.
Despite these considerations, the clinical relevance of this report resides in the fact that it is the first pharmacogenetic report of an association of MPH adverse effects with a gene involved in the pharmacokinetics of this drug. Therefore, the present results should be replicated in larger and independent samples.
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